Quarterly ResultMay 13, 2026, 05:22 PM
Microbot Medical Q1 Net Loss $(3.67)M; Reports First Revenue $105K
AI Summary
Microbot Medical Inc. reported a net loss of $(3.67) million for the first quarter of 2026, an increase from $(2.60) million in the same period last year. The company generated its first revenue of $105K, primarily from the sale of its LIBERTY® Endovascular Robotic Systems. Operating loss widened to $(4.32) million, driven by a significant increase in sales, general and administrative expenses. Despite the losses, the company maintains a strong liquidity position with approximately $72.5 million in cash and marketable securities, which management believes is sufficient to fund operations for over twelve months.
Key Highlights
- Net loss increased to $(3.67)M in Q1 2026 from $(2.60)M in Q1 2025.
- Reported first-time revenue of $105K in Q1 2026, up from $0 in Q1 2025.
- Operating loss widened to $(4.32)M in Q1 2026 from $(3.02)M in Q1 2025.
- Sales, general and administrative expenses rose to $(3.03)M from $(1.56)M.
- Cash and cash equivalents decreased to $3.66M from $3.91M since Dec 31, 2025.
- Marketable securities decreased to $68.84M from $74.68M since Dec 31, 2025.
- Net cash used in operating activities increased to $(5.05)M from $(2.87)M.
- Company holds $72.5M in cash and marketable securities, sufficient for >12 months.